Walter Storkus, PhD

Summary

My laboratory studies tumor immunobiology and designs immunotherapies for the treatment of cancer based on results from translational modeling. My near-term research goal remains the development of novel phase I/II clinical trials for the immunotherapy of patients with cancer, with a focus on melanoma and renal cell carcinoma (RCC). Such treatment modalities include dendritic cell (DC)-based vaccines, vascular targeted inhibitors, innate immune cell activators and combination protocols integrating immune checkpoint inhibitors. The study of biomarkers of response to interventional immunotherapy including tumor-associated tertiary lymphoid structures (TLS) is also an area of active research in my group.